SCHEDULE: Alyeska Investment Group Discloses 9.7% Stake in Fractyl Health

Alyeska Investment Group, L.P. and its affiliates have disclosed a 9.7% beneficial ownership stake in Fractyl Health's Class A Common Stock.

Summary

• Alyeska Investment Group, L.P., Alyeska Fund GP, LLC, and Anand Parekh have reported beneficial ownership of 13,267,417 shares of Fractyl Health's Class A Common Stock.
• This ownership represents 9.7% of the outstanding Class A Common Stock.
• The stake includes 5,648,371 shares of Common Stock and warrants to purchase an additional 7,619,046 shares.
• The percentage calculation is based on an assumed 137,044,440 outstanding Common Stock, as per Fractyl Health's Prospectus filed with the SEC on November 6, 2025.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a reputable investment group like Alyeska is generally viewed positively as it signals institutional confidence and potential future interest in the stock. The inclusion of warrants also suggests a belief in long-term growth.

Positives

• A significant institutional investor, Alyeska Investment Group, has taken a substantial 9.7% stake in Fractyl Health, potentially signaling confidence in the company's future prospects.
• The investment includes both common stock and warrants, indicating a long-term interest and potential upside belief from the reporting persons.

Risks

• The filing itself does not detail specific risks related to Fractyl Health's operations or financial health; it is a disclosure of ownership.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Fractyl Health or the reporting persons regarding the issuer's future performance.

Industry Context

This filing indicates a notable institutional investment in Fractyl Health, a company likely operating in the healthcare or biotechnology sector given its name. Such investments by prominent groups like Alyeska can attract further investor attention to the company and its industry peers, potentially validating its market position or future potential within the broader healthcare innovation landscape.

Stakeholder Impact

• Shareholders: Existing shareholders may view this as a positive signal, potentially leading to increased investor confidence and demand for the stock.
• Company Management: The investment could be seen as a vote of confidence in the company's strategy and future.

Key Dates

Recommendation

While the disclosure of a significant institutional stake by Alyeska Investment Group is a positive signal, a Schedule 13G filing primarily reports ownership and does not provide operational or financial performance details. Investors should 'hold' and await further financial disclosures from Fractyl Health to make a more informed decision, using this filing as an indicator of institutional interest rather than a direct performance metric.

Keywords

Fractyl Health, Alyeska Investment Group, Schedule 13G, beneficial ownership, Class A Common Stock, institutional investment, equity stake, warrants, SEC filing